Hip Avascular Necrosis

Hip · Condition

Hip Avascular Necrosis: Options and What the Evidence Actually Shows

Early-stage AVN is one of the cleanest mechanistic cases in regenerative orthopedics — and still a specialist decision.

Anatomy and clinical context

AVN is bone death in the femoral head from disrupted blood supply. Collapse converts a joint-preserving problem into an arthroplasty problem.

Staging (e.g. ARCO) drives whether core decompression ± adjuncts are reasonable versus proceeding to replacement.

The standard ladder of care

Conservative care first, then injections, then surgery when indicated. Cell therapy belongs inside that conversation — not above it.

  1. 1

    Conservative care

    Protected weight bearing and risk-factor management in very early disease.

  2. 2

    Injections

    Core decompression ± bone graft or orthobiologic adjuncts in selected pre-collapse stages.

    Autologous cell approaches enter here — dose and donor age are what change the conversation.

  3. 3

    Surgery

    Total hip arthroplasty after collapse or failed joint-preserving care.

Availability

Where this procedure is available

Availability requires both an authorizing state statute and a Forever Labs network physician. Status updates when we publish a provider in Payload — no code change required.

Available now

  • Florida

    Orthopedic authorization

    SB 1768 · Ch. 2025-185; Fla. Stat. §§ 458.3245, 459.0127

    • Dr. Moises Irizarry-Roman, MD · Miami, Florida
    • Dr. Tad DeWald, MD · Miami, Florida
    • Dr. Joshua Hackel, MD · Gulf Breeze, Florida
    View network providers

Law open — network coming

  • Tennessee

    HB 2246 · Tenn. Code Ann. Titles 63 & 68 (as amended)

    Forever Labs network recruitment in progress — no committed quarter yet

    Rulemaking still pending

  • Wyoming

    SF 0048 — Stem Cell Freedom Act · W.S. §§ 35-4-1101 through 35-4-1106

    Forever Labs network recruitment in progress — no committed quarter yet

    Physician must be listed on the Board of Medicine registry

Pending legislation

  • Arizona

    SB 1214 — Bill still pending; definition would expressly cover culture-expanded cells

Different pathway

These states have regenerative-medicine laws, but not Florida-style orthopedic authorization. Labeled with their actual scope.

  • Review-board pathway

    Montana

    SB 535 — Phase 1 safety data + review-board approval required; not condition-specific

  • Right-to-try

    Texas

    HB 810 + HB 5147 — Restricted to severe chronic or terminal illness

  • Right-to-try

    Mississippi

    Stem cell investigational access — Right-to-try style; not a general orthopedic authorization

  • Birth tissue only

    Utah

    SB 199 / SB 275 — Allogeneic birth tissue only — not autologous MSC banking

Not in one of these states?

Banking and shipping are nationwide. Your cells can be shipped to your physician, but the procedure itself has to be arranged with your doctor first.

Browse the full provider network

Verified as of July 31, 2026. Statute claims cite primary sources. Forward-looking network quarters are Forever Labs targets, not legislative promises. Therapies described here are not FDA-approved.

Evidence

Where cell therapy fits

AVN attracts regenerative interest because biology and timing matter. Evidence quality varies; choose centers that stage honestly.

1
Randomized trial
1
Expanded-cell approvals
Largest trial (participants)

The honest read — Same-day products keep landing at parity. The approved products that show more are the expanded ones — which makes dose, not enthusiasm, the variable worth acting on.

  1. 01

    Pre-collapse vs post-collapse changes everything.

  2. 02

    Cell adjuncts are not magic — they are tools inside staged care.

  3. 03

    Banking younger cells may matter if expanded autologous products become part of future protocols.

The sources

Both directions, cited plainly — the trials that found no advantage and the approvals that show what engineered dose looks like.

  • Regulatory approvalIndia

    Stempeucel

    Approved product (India) · Regulatory approval (2020)

    Culture-expanded MSC product approved in India — example of dose-enabled products showing clinical pathway beyond same-day unexpanded injectates.

  • Randomized trial

    Shapiro 2017

    Shapiro et al. · AJSM (2017)

    BMAC vs saline in the same patient's other knee — no difference on primary outcomes.

You are your own best donor

The most powerful medicine you'll ever use is already inside you.

Your stem cells are the body's repair crew — the same cells that build, heal, and renew tissue your whole life. Bank them now, at their most potent, and keep that regenerative power on your side for the years ahead.

  1. Your cells, your biology, zero rejection.

    No donor waitlist, no match required. These are your own stem cells — the safest, most natural material medicine has to work with.

  2. Younger cells are stronger cells.

    Your stem cells are more vigorous today than they'll ever be again. Bank them now and you lock in that youthful potency — 35-year-old cells stay available to the 55-year-old you.

  3. One bank becomes a lasting supply.

    Culture expansion turns a single collection into dose after dose — enough for a full course of treatment, not a one-shot souvenir. Rolling out now as our Florida cGMP lab comes online.

  4. Ready the moment you need it.

    When you and your physician decide it's time, your cells are waiting at peak potency — so the treatment works with the best version of you.